Key GOP senators expressed skepticism towards President Trump's proposal to cut NIH funding and reorganize HHS, indicating potential congressional resistance similar to last year. This matters as it could preserve critical research funding and prevent disruptive changes within health agencies, maintaining stability for developers and tech professionals in biotech and pharma. Watch for the development of a congressional spending package that may override administration cuts.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



